NASDAQ: MLTX
MoonLake ImmunotherapeuticsCIK 0001821586 · Pharmaceutical Preparations
Each report below shows a 3-bullet preview. Free accounts read 3 full reports a month — narrative summary, section diffs, and EDGAR-cited quotes.
Sign up freeWant to see a complete report first? Today's free report (THRM 10-Q) is open in full — no account needed.
Summary not yet generated.
Summary not yet generated.
Partner
Trade MLTX commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
MoonLake shareholders approve 5M share increase to equity compensation plan
5 material changes detected. Sign up free to read the summary.
MoonLake locks in commercial manufacturing with Vetter, faces penalties if orders fall short
5 material changes detected. Sign up free to read the summary.
MoonLake faces securities litigation as BLA filing nears; Q3 2026 submission confirmed
5 material changes detected. Sign up free to read the summary.
MoonLake gains FDA alignment on drug approval pathway for hidradenitis suppurativa treatment
2 material changes detected. Sign up free to read the summary.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Latest financial statements
From 10-Q filed May 11, 2026 (period ending Mar 31, 2026). SEC XBRL (companyfacts) — not generated by the model.
Consolidated Statements of Operations (Unaudited)
| Description | Q1 ended Mar 31, 2026 | Q1 ended Mar 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | 54.5 | 36.5 |
| General and administrative | 15.5 | 11.0 |
| Total operating expenses | 70.0 | 47.5 |
| Operating income | (70.0) | (47.5) |
| Interest expense | 2.3 | 0.02 |
| Income tax expense/(benefit) | 0.6 | 0.2 |
| Net income | (69.7) | (39.9) |
| Basic earnings per share | (0.98) | (0.63) |
| Diluted earnings per share | (0.98) | (0.63) |
Consolidated Balance Sheets (Unaudited)
| Description | Mar 31, 2026 | Mar 31, 2025 |
|---|---|---|
| Current assets: | ||
| Cash and equivalents | 298.5 | 271.6 |
| Short-term investments | 59.4 | 208.6 |
| Other receivables, net | 5.8 | 3.0 |
| Prepaid expenses and other current assets | 33.0 | 23.1 |
| Total current assets | 396.6 | 506.3 |
| Property, plant and equipment, net | 0.5 | 0.7 |
| Operating lease right-of-use assets, net | 1.9 | 2.6 |
| Deferred income taxes and other assets | 1.3 | 1.7 |
| TOTAL ASSETS | 400.4 | 511.3 |
| Current liabilities: | ||
| Current portion of operating lease liabilities | 0.9 | 1.4 |
| Income taxes payable | 1.4 | 2.2 |
| Other current liabilities | 43.8 | 20.3 |
| Total current liabilities | 46.1 | 24.0 |
| Long-term debt | 99.0 | 73.0 |
| Operating lease liabilities | 0.9 | 1.1 |
| Total liabilities | 146.3 | 98.7 |
| Shareholders' equity: | ||
| Capital in excess of stated value | 786.3 | 680.7 |
| Accumulated other comprehensive income (loss) | 0.3 | 2.4 |
| Retained earnings (deficit) | (532.6) | (275.5) |
| Total shareholders' equity | 254.0 | 407.5 |
| TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | 400.4 | 511.3 |
Consolidated Statements of Cash Flows (Unaudited)
| Description | Q1 ended Mar 31, 2026 | Q1 ended Mar 31, 2025 |
|---|---|---|
| Operating Activities: | ||
| Net cash from operating activities | (66.3) | (38.1) |
| Investing Activities: | ||
| Net cash from investing activities | 0.10 | 56.2 |
| Financing Activities: | ||
| Net cash from financing activities | 30.6 | 73.1 |
| Net increase/(decrease) in cash | (36.0) | 91.1 |
Amounts in millions USD; EPS as reported. Line labels are presentation-friendly mappings of filer XBRL tags — not a re-audit of the full statements. Use EDGAR for interactive notes and detail. Interactive statements & notes on EDGAR ↗